Escherichia coli CRISPR arrays from early life fecal samples preferentially target prophages

Moïra B. Dion, Shiraz A. Shah, Ling Deng, Jonathan Thorsen, Jakob Stokholm, Karen A. Krogfelt, Susanne Schjørring, Philippe Horvath, Antoine Allard, Dennis S. Nielsen, Marie Agnès Petit, Sylvain Moineau

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

CRISPR-Cas systems are defense mechanisms against phages and other nucleic acids that invade bacteria and archaea. In Escherichia coli, it is generally accepted that CRISPR-Cas systems are inactive in laboratory conditions due to a transcriptional repressor. In natural isolates, it has been shown that CRISPR arrays remain stable over the years and that most spacer targets (protospacers) remain unknown. Here, we re-examine CRISPR arrays in natural E. coli isolates and investigate viral and bacterial genomes for spacer targets using a bioinformatics approach coupled to a unique biological dataset. We first sequenced the CRISPR1 array of 1769 E. coli isolates from the fecal samples of 639 children obtained during their first year of life. We built a network with edges between isolates that reflect the number of shared spacers. The isolates grouped into 34 modules. A search for matching spacers in bacterial genomes showed that E. coli spacers almost exclusively target prophages. While we found instances of self-targeting spacers, those involving a prophage and a spacer within the same bacterial genome were rare. The extensive search for matching spacers also expanded the library of known E. coli protospacers to 60%. Altogether, these results favor the concept that E. coli's CRISPR-Cas is an antiprophage system and highlight the importance of reconsidering the criteria use to deem CRISPR-Cas systems active.

Original languageEnglish
Article numberwrae005
JournalThe ISME journal
Volume18
Issue number1
ISSN1751-7362
DOIs
Publication statusPublished - 8 Jan 2024

Funding

This work was supported by the Joint Programming Initiative \"Healthy Diet for a Healthy Life,\" including the Danish Agency for Science and Higher Education and the Canadian Institutes of Health Research (Team grant on Intestinal Microbiomics, Institute of Nutrition, Metabolism, and Diabetes, grant number 143924). M.B.D. is recipient of graduate scholarships from the Fonds de Recherche du Qu\u00E9bec-Nature et Technologies (259257) as well as Sentinel North and is a recipient of the Goran-Enhorning Graduate Student Research Award from the Canadian Allergy, Asthma, and Immunology Foundation. This research was enabled in part by support provided by Calcul Qu\u00E9bec (www.calculquebec. ca) and Digital Research Alliance of Canada (alliancecan.ca). J.T. is supported by the BRIDGE Translational Excellence Programme (bridge.ku.dk) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation, grant agreement no. NNF18SA0034956. AA acknowledges financial support from the Sentinelle Nord initiative of the Canada First Research Excellence Fund and from the Natural Sciences and Engineering Research Council of Canada (project 2019-05183). S.M. holds the Tier 1 Canada Research Chair in Bacteriophages (950-232136).

Keywords

  • bacteriophage
  • CRISPR
  • E. coli
  • gut
  • microbiome
  • phage
  • phage resistance
  • virome

Cite this